DarioHealth Corp. 8-K

What Happened
DarioHealth Corp. (DRIO) announced on March 30, 2026 (Item 1.01 on Form 8-K) that it entered into a sales agreement with A.G.P./Alliance Global Partners to sell, from time to time, up to $20,000,000 of its common stock through an “at-the-market” (ATM) offering under Rule 415. The sales agent may act as agent or principal and any sales will be made under the Company’s effective shelf registration statement on Form S-3 (File No. 333-294454), declared effective March 27, 2026, with an ATM prospectus supplement filed March 30, 2026. The Company is not obligated to sell shares and may suspend or terminate the program.

Key Details

• Up to $20,000,000 of common stock may be sold through the ATM offering.
• Agent compensation: fixed commission of 3.00% of gross proceeds.
• Expense reimbursements: up to $35,000 initially, $3,500 per calendar quarter thereafter, plus up to $5,000 per ATM “refresh”; Company also pays FINRA and certain per-share selling costs (up to $0.002/share).
• Proceeds may be used for commercial/sales & marketing, R&D, M&A, corporate purposes, repayment of indebtedness (including under the Callodine credit facility) and general working capital. The program ends upon sale of all shares, expiration of the registration (3 years from effectiveness), or termination by either party.

Why It Matters
This ATM facility gives DarioHealth a flexible way to raise capital as needed without a single large offering. For investors, ATM sales can be dilutive because new shares may be issued as they are sold, and transaction costs (commissions and fees) will reduce net proceeds. The filing makes clear there is no mandatory issuance schedule — the company controls timing — and the agreement includes customary indemnities and counsel opinion filed with the 8-K.